Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM202RY gene therapy in acute myocardial infarction
NCT03404024Phase 2Withdrawn
- Sponsor
- Helixmith
- Start
- Jan 2018
- Primary completion
- Aug 2019
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 2 trial of Engensis in acute myocardial infarction (AMI), sponsored by Helixmith. Planned start Jan 2018; status: withdrawn.
02
Drugs
Engensis
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT03404024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404024.